Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Guard Therapeutics International AB (publ) is a Swedish pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for the diagnosis and management of acute kidney injuries. A key offering is ROSGard, a biological drug candidate designed to prevent kidney impairment through the protection, purification, and restoration of affected cells and tissues. Founded in 2008, the company operated as A1M Pharma AB (publ) until its renaming to Guard Therapeutics International AB (publ) in October 2019. Its headquarters are located in Stockholm, Sweden.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.
Target Price
The average target price of GUARD.ST is 1.75 and suggests 19.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to